Bürokratische Hürden und Lösungsansätze klinischer Krebsforschung in Deutschland

Clinical trials are essential for the evaluation of new medical treatments. Their aim is to improve treatment options and insights into disease management. However, increasing bureaucracy is jeopardising the sustainability of research, particularly in academic studies. Complex processes slow down the initiation and progress of studies, and put a strain on research teams and resources. There is an urgent need to simplify these processes in order to optimise patient care. While adherence to ethical and regulatory standards remains paramount, streamlining administrative steps must occur to increase efficiency and promote research. The COVID-19 pandemic has shown that simplification is possible without compromising quality or ethics. A solution-oriented dialogue between all stakeholders is crucial to secure the future of clinical trials.